{
    "clinical_study": {
        "@rank": "97534", 
        "arm_group": {
            "arm_group_label": "Azacytidine + Donor lymphocyte infusion", 
            "arm_group_type": "Experimental", 
            "description": "Azacytidine will be administered subcutaneously for 5 days. During the first cycle, a dose of 100mg/m2/day will be used and for the following cycles a dose of 35mg/m2/day will be administered. Each cycle will consist in 28 days. All patients will receive at least 6 cycles of Azacytidine and the total number of cycles will depend on the response to treatment.\nDonor lymphocyte infusion will be performed on day 1 of cycle 2, 4 and 6 of Azacytidine. The amount of cells infused will depend on donor origin."
        }, 
        "brief_summary": {
            "textblock": "The present project is a multicenter, phase II trial which aims at evaluating if the\n      administration of azacytidine (Vidaza\u00ae) combined to donor lymphocyte infusion (DLI) could\n      improve the response rate to DLI in the population of patients with relapsed acute myeloid\n      leukemia (AML) and myelodysplastic syndrome  (MDS) after allogeneic hematopoietic stem cell\n      transplantation."
        }, 
        "brief_title": "Azacytidine and Lymphocytes in Relapse of AML or MDS After Allogeneic Stem Cell Transplantation.", 
        "completion_date": {
            "#text": "December 2022", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Acute Myelogenous Leukemia", 
            "Myelodysplastic Syndrome"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Leukemia", 
                "Leukemia, Myeloid, Acute", 
                "Leukemia, Myeloid", 
                "Myelodysplastic Syndromes", 
                "Preleukemia"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Patients:\n\n               -  Age \u2265 18 years\n\n               -  Be able to understand and sign informed consent\n\n               -  Fertile patients must use a reliable contraception method\n\n          2. Disease status at transplantation:\n\n               -  AML in first or subsequent complete remission (< 5% marrow blasts)\n\n               -  MDS with less than 10% marrow blasts at the time of transplantation\n\n          3. Transplantation:\n\n               -  Allogeneic transplantation using a sibling or unrelated donor with   matching in\n                  10/10 alleles (HLA-A, B, C, DRB1, DQB1) or maximum of one allele or one antigen\n                  or 1 antigen + 1 allele or 1 antigen + 1 DQB1 antigen or 2 alleles mismatches.\n\n               -  Myeloablative or reduced-intensity conditioning\n\n               -  Second transplantation is allowed\n\n               -  Donor is willing to donate lymphocytes\n\n          4. Clinical situation:\n\n               -  Cytological relapse after allo-SCT defined as the recurrence of more than 5%\n                  blasts on bone marrow aspiration (AML) or evidence of MDS\n\n               -  Immunophenotypic relapse defined as the recurrence of an abnormal phenotype on\n                  flow cytometry in bone marrow aspirate (only in case of a specific phenotype).\n\n               -  Cytogenetic or molecular relapse defined as the persistence or recurrence of a\n                  cytogenetic abnormality or molecular marker in bone marrow aspiration or\n                  peripheral blood. WT1 expression is not considered as reliable marker for\n                  relapse in this protocol but FLT3-ITD, NPM1, CEBPA, or translocation-specific\n                  markers (such as MLL-PTD, AML-ETO, CBFB-MYH11) are.\n\n          5. Immunosuppressive therapy should have been withdrawn in the month preceding inclusion\n\n        Exclusion Criteria:\n\n          -  More than 30% marrow blasts at the time of inclusion\n\n          -  Extramedullary relapse including CNS involvement\n\n          -  ECOG Performance status > 2\n\n          -  Active acute grade II-IV GvHD at the time of inclusion\n\n          -  Active chronic GvHD requiring systemic therapy at the time of inclusion\n\n          -  Uncontrolled infection\n\n          -  HIV positive\n\n          -  Acute or chronic heart failure (NYHA class III or IV) or symptomatic ischemic heart\n             disease or ejection fraction < 35% or uncontrolled arrhythmia\n\n          -  Severe liver failure (total bilirubin > 3 mg/dL, SGPT > 4 X upper normal limit)\n\n          -  Severe pulmonary failure (corrected DLCo < 35%)\n\n          -  Terminal renal failure requiring dialysis\n\n          -  Severe neurological or psychiatric disorders\n\n          -  Concurrent investigational drug.\n\n          -  Other treatment for relapse, except for hydroxyurea.\n\n          -  Female who is pregnant or breastfeeding"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "50", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 16, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02017457", 
            "org_study_id": "BHS-TC-10"
        }, 
        "intervention": [
            {
                "arm_group_label": "Azacytidine + Donor lymphocyte infusion", 
                "description": "On day 1 of cycle 2, 4 and 6 of Azacytidine, patients will be infused with donor lymphocytes.\nPatients with a sibling donor will receive:\n1x10exp7 CD3+/kg on day 1 of cycle 2\n5x10exp7 CD3+/kg on day 1 of cycle 4\n1x10exp8 CD3+/kg on day 1 of cycle 6\nPatients with an unrelated donor will receive:\n1x10exp6 CD3+/kg on day 1 of cycle 2\n5x10exp6 CD3+/kg on day 1 of cycle 4\n1x10exp7 CD3+/kg on day 1 of cycle 6", 
                "intervention_name": "Donor lymphocyte infusion", 
                "intervention_type": "Biological", 
                "other_name": "DLI"
            }, 
            {
                "arm_group_label": "Azacytidine + Donor lymphocyte infusion", 
                "description": "Cycle 1: Subcutaneous administration of 100mg/m2/day for 5 days.\nCycle 2: Subcutaneous administration of 35mg/m2/day for 5 days. Cycles will be administered every 28 days.\nAll patients will receive at least 6 cycles of Azacytidine. In case of complete remission after cycle 5, 2 additionnal cycles will be administered after achievement of complete remission.\nIn case of stable disease or partial response, Azacytidine will be continued until progression.\nIn case of disease progression after cycle 6, Azacytidine will be stopped.", 
                "intervention_name": "Azacytidine", 
                "intervention_type": "Drug", 
                "other_name": "Vidaza"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Azacitidine"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Hematology", 
            "Acute Myelogenous Leukemia", 
            "Myelodysplasic syndrome", 
            "Allogeneic stem cell transplantation", 
            "Donor lymphocyte infusion", 
            "DLI", 
            "Azacytidine", 
            "Vidaza", 
            "Overall response rate", 
            "Relapse"
        ], 
        "lastchanged_date": "April 7, 2014", 
        "location": [
            {
                "contact": {
                    "email": "pierre.zachee@zna.be", 
                    "last_name": "Pierre Zachee, MD, PhD", 
                    "phone": "32-3-2177111"
                }, 
                "facility": {
                    "address": {
                        "city": "Antwerpen", 
                        "country": "Belgium", 
                        "zip": "2060"
                    }, 
                    "name": "Ziekenhuis Netwerk Antwerpen"
                }, 
                "investigator": {
                    "last_name": "Pierre Zachee, MD, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "dominik.selleslag@azbrugge.be", 
                    "last_name": "Dominik Selleslag, MD", 
                    "phone": "32-50-453060"
                }, 
                "contact_backup": {
                    "email": "tom.lodewyck@azbrugge.be", 
                    "last_name": "Tom Lodewyck, MD", 
                    "phone": "32-50-453060"
                }, 
                "facility": {
                    "address": {
                        "city": "Brugge", 
                        "country": "Belgium", 
                        "zip": "8000"
                    }, 
                    "name": "AZ Sint-Jan Brugge"
                }, 
                "investigator": [
                    {
                        "last_name": "Dominik Selleslag, MD", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Tom Lodewyck, MD", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "philippe.lewalle@bordet.be", 
                    "last_name": "Philippe Lewalle, MD, PhD", 
                    "phone": "32-2-5417208"
                }, 
                "facility": {
                    "address": {
                        "city": "Brussels", 
                        "country": "Belgium", 
                        "zip": "1000"
                    }, 
                    "name": "Institut Jules Bordet"
                }, 
                "investigator": {
                    "last_name": "Philippe Lewalle, MD, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "zwi.berneman@uza.be", 
                    "last_name": "Zwi Berneman, MD, PhD", 
                    "phone": "32-3-2204111"
                }, 
                "facility": {
                    "address": {
                        "city": "Edegem", 
                        "country": "Belgium", 
                        "zip": "2650"
                    }, 
                    "name": "Universitair Ziekenhuis Antwerpen"
                }, 
                "investigator": {
                    "last_name": "Zwi Berneman, MD, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "Lucien.Noens@Ugent.be", 
                    "last_name": "Lucien Noens, MD, PhD", 
                    "phone": "32-9-3323464"
                }, 
                "contact_backup": {
                    "email": "Tessa.Kerre@Ugent.be", 
                    "last_name": "Tessa Kerre, MD, PhD", 
                    "phone": "32-9-3323464"
                }, 
                "facility": {
                    "address": {
                        "city": "Gent", 
                        "country": "Belgium", 
                        "zip": "9000"
                    }, 
                    "name": "Universitair Ziekenhuis Gent"
                }, 
                "investigator": [
                    {
                        "last_name": "Lucien Noens, MD, PhD", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Tessa Kerre, MD, PhD", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "nicoles.Straetmans@scarlet.be", 
                    "last_name": "Nicole Straetmans, MD, PhD", 
                    "phone": "32-64-233989"
                }, 
                "facility": {
                    "address": {
                        "city": "Haine-St-Paul", 
                        "country": "Belgium", 
                        "zip": "7100"
                    }, 
                    "name": "Hopital de Jolimont"
                }, 
                "investigator": {
                    "last_name": "Nicole Straetmans, MD, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "Rik.Schots@uzbrussel.be", 
                    "last_name": "Rik Schots, MD, PhD", 
                    "phone": "32-2-4763105"
                }, 
                "contact_backup": {
                    "email": "Ann.Debecker@uzbrussel.be", 
                    "last_name": "Ann De Becker, MD", 
                    "phone": "32-2-4763105"
                }, 
                "facility": {
                    "address": {
                        "city": "Jette", 
                        "country": "Belgium", 
                        "zip": "1090"
                    }, 
                    "name": "Universitair Ziekenhuis Brussel"
                }, 
                "investigator": [
                    {
                        "last_name": "Rik Schots, MD,PhD", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Ann De Becker, MD", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "Johan.Maetens@uzleuven.be", 
                    "last_name": "Johan Maertens, MD,PhD", 
                    "phone": "32-16-332211"
                }, 
                "contact_backup": {
                    "email": "Helene.Schoemans@uzleuven.be", 
                    "last_name": "H\u00e9l\u00e8ne Schoemans, MD", 
                    "phone": "32-16-332211"
                }, 
                "facility": {
                    "address": {
                        "city": "Leuven", 
                        "country": "Belgium", 
                        "zip": "3000"
                    }, 
                    "name": "Universitair Ziekenhuis Leuven"
                }, 
                "investigator": [
                    {
                        "last_name": "Johan Maertens, MD,PhD", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "H\u00e9l\u00e8ne Schoemans, MD", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "yves.beguin@chu.ulg.ac.be", 
                    "last_name": "Yves Beguin, MD, PhD", 
                    "phone": "32-4-3667201"
                }, 
                "contact_backup": {
                    "email": "F.Baron@ulg.ac.be", 
                    "last_name": "Fr\u00e9d\u00e9ric Baron, MD, PhD", 
                    "phone": "32-4-3667201"
                }, 
                "facility": {
                    "address": {
                        "city": "Li\u00e8ge", 
                        "country": "Belgium", 
                        "zip": "4000"
                    }, 
                    "name": "CHU Li\u00e8ge"
                }, 
                "investigator": [
                    {
                        "last_name": "Yves Beguin, MD, PhD", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Fr\u00e9d\u00e9ric Baron, MD, PhD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Evelyne Willems, MD, PhD", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "ddeeren@hhr.be", 
                    "last_name": "Dries Deeren, MD", 
                    "phone": "32-51-237437"
                }, 
                "facility": {
                    "address": {
                        "city": "Roeselare", 
                        "country": "Belgium", 
                        "zip": "8800"
                    }, 
                    "name": "Hartziekenhuis Roeselare Menen"
                }, 
                "investigator": {
                    "last_name": "Dries Deeren, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "Xavier.Poire@uclouvain.be", 
                    "last_name": "Xavier Poir\u00e9, MD", 
                    "phone": "32-2-7641809"
                }, 
                "facility": {
                    "address": {
                        "city": "Woluwe-Saint-Lambert", 
                        "country": "Belgium", 
                        "zip": "1200"
                    }, 
                    "name": "Cliniques Universitaires Saint-Luc"
                }, 
                "investigator": {
                    "last_name": "Xavier poir\u00e9, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "Carlos.Graux@uclouvain.be", 
                    "last_name": "Carlos Graux, MD,PhD", 
                    "phone": "32-81-423831"
                }, 
                "facility": {
                    "address": {
                        "city": "Yvoir", 
                        "country": "Belgium", 
                        "zip": "5530"
                    }, 
                    "name": "CHU Mont-Godinne"
                }, 
                "investigator": {
                    "last_name": "Carlos Graux, MD,PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Belgium"
        }, 
        "number_of_arms": "1", 
        "official_title": "Sequential Administration of 5-azacytidine (AZA) and Donor Lymphocyte Infusion (DLI) for Patients With Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndrome (MDS) in Relapse After Allogeneic Stem Cell Transplantation.", 
        "other_outcome": [
            {
                "measure": "Immune reconstitution", 
                "safety_issue": "No", 
                "time_frame": "On day 1 of each cycle until cycle 6, then every 3 months for a year and at 1.5 and 2 years after cycle 6"
            }, 
            {
                "measure": "Treg expansion", 
                "safety_issue": "No", 
                "time_frame": "On day 1 of each cycle until cycle 6, then every 3 months for a year and at 1.5 and 2 years after cycle 6"
            }
        ], 
        "overall_contact": {
            "email": "Xavier.Poire@uclouvain.be", 
            "last_name": "Xavier Poir\u00e9, MD", 
            "phone": "32-2-7641809"
        }, 
        "overall_contact_backup": {
            "email": "Carlos.Graux@uclouvain.be", 
            "last_name": "Carlos Graux, MD,PhD", 
            "phone": "32-81-423831"
        }, 
        "overall_official": [
            {
                "affiliation": "Cliniques universitaires Saint-Luc", 
                "last_name": "Xavier Poir\u00e9, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Cliniques Universitaires Mont-Godinne", 
                "last_name": "Carlos Graux, MD, PhD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Belgium: Federal Agency for Medicinal Products and Health Products", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2022", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "To assess the response rate to DLI by the combination with azacytidine in the population of patients with relapsed AML and MDS after allo-SCT.", 
            "measure": "Response rate", 
            "safety_issue": "No", 
            "time_frame": "Will be evaluated at day 24 of cycle 1, 3 and 5. Then every 3 months for a year after cycle 6 thereafter at 1.5 and 2 years after cycle 6"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02017457"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University Hospital of Mont-Godinne", 
            "investigator_full_name": "Carlos Graux, MD, PhD", 
            "investigator_title": "Professor", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "Disease-free survival", 
                "safety_issue": "No", 
                "time_frame": "2 years after cycle 6"
            }, 
            {
                "measure": "Overall survival", 
                "safety_issue": "No", 
                "time_frame": "2 years after cycle 6"
            }, 
            {
                "description": "Evaluate haematological and non-haematological toxicities and safety of the planned therapy.", 
                "measure": "Toxicity", 
                "safety_issue": "Yes", 
                "time_frame": "At the beginning of each cycle and at the discretion of the investigator until cycle 6, then monthly for 6 months, thereafter every 3 months for 1.5 years"
            }, 
            {
                "measure": "Incidence and severity of GvHD", 
                "safety_issue": "Yes", 
                "time_frame": "At the beginning of each cycle and at the discretion of the investigator until cycle 6, then monthly for 6 months, thereafter every 3 months for 1.5 years"
            }, 
            {
                "measure": "Incidence and severity of infections", 
                "safety_issue": "Yes", 
                "time_frame": "At the beginning of each cycle and at the discretion of the investigator until cycle 6, then monthly for 6 months, thereafter every 3 months for 1.5 years"
            }
        ], 
        "source": "University Hospital of Mont-Godinne", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Celgene Europe Ltd", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Belgian Hematological Society", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "Carlos Graux, MD, PhD", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}